|
Aiko's patented portfolio of compounds includes naltrexone / naloxone analogs, including naltrexol, naltrexamine and naloxol derivatives. Each compound has been demonstrated to display neutral antagonist properties at the mu opioid receptor.
| |
June, 2009
6β-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice
February, 2005
Basal opioid receptor activity, neutral antagonists, and therapeutic
opportunities
June, 2005
In vivo characterization of 6B-naltrexone, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice
February, 2004
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
June, 2001
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
|
